OnKure Therapeutics, Inc. (OKUR) Stock Forecast & Price Target
OnKure Therapeutics, Inc. · NASDAQ
$3.97-0.08 (-1.98%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering OnKure Therapeutics, Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $21.00 to $21.00, so the covering firms are broadly aligned. The average target of $21.00 sits 429% above the current $3.97. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.54 next quarter toward $-2.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to OnKure Therapeutics, Inc.
As of Jul, 1 of 1 firms rate OKUR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OKUR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.54
Range $-0.69 – $-0.41 · 4 analysts · -51% YoY
Next period, 4 analysts expect OnKure Therapeutics, Inc. to earn $-0.54 a share (range $-0.69 – $-0.41), versus $-1.09 a year earlier. Full-year consensus is $-2.36, growing to $-2.13 the year after.
REVENUE · NEXT QUARTER
$125.0K
Range $0 – $500.0K · 4 analysts
Revenue is expected to reach $125.0K (range $0 – $500.0K). Full-year consensus is $375.0K, rising to $666.7K next year.
Top analysts covering OnKure Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OKUR.
#1
Andrew Berens
Leerink Partners · Rank #167
Buy
$33.00+731.2% to target
Overall win rate
50%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$21.00+429.0% to target
Overall win rate
38%
+ Follow
#3
JM
Jonathan Miller
Evercore ISI
Buy
No targeton OKUR
Coverage
—
+ Follow
#4
MB
Matt Biegler
Oppenheimer
Buy
$30.00+655.7% to target
Coverage
—
+ Follow
#5
SR
Soumit Roy
Jones Trading
Buy
$32.00+706.0% to target
Coverage
—
+ Follow
OKUR stock forecast FAQ
What is OKUR's average 12-month price target?+
The 1 analysts with a live target average $21.00 for OnKure Therapeutics, Inc. over the next 12 months, ranging from a $21.00 high to a $21.00 low.
Is OKUR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover OKUR?+
1 analysts have an active rating on OnKure Therapeutics, Inc., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering OKUR?+
Among analysts who currently cover OKUR, Andrew Berens of Leerink Partners has the strongest overall Quantellect track record (Rank #167). Their current call is Buy with a $33.00 target.
What is OnKure Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.54 per share (range $-0.69 – $-0.41) across 4 analysts. Full-year EPS is projected at $-2.36, rising to $-2.13 the following year.
How much revenue is OnKure Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $125.0K (range $0 – $500.0K). Full-year revenue is projected at $375.0K, growing to $666.7K next year.
Have analysts been upgrading or downgrading OKUR lately?+
As of Jul, 1 of 1 firms rate OKUR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OKUR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
